Related Experiment Video
Updated: Aug 14, 2026
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Lamotrigine prophylaxis is associated with reduced aura frequency in patients with burdensome migraine aura: a
Sena Uzun1,2,3, Ulf Frejvall1, Hulya Karatas4,5
1SkåNeuro Neurology Clinic, Lund, Sweden.
Introduction:
Migraine aura affects approximately one-third of migraine patients. In some individuals, aura remains highly disabling due to the lack of effective, targeted treatment options. This study evaluates the effectiveness and long-term management of lamotrigine (LTG) in a clinical Cohort specifically burdened by frequent or severe aura.
Methods:
A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022. The primary outcome was the proportion of patients achieving ≥50% reduction in monthly aura days (MADs) following LTG prophylaxis.
Results:
A total of 81 patients were included in the study. A reduction in mean MADs from 6.9 ± 7.5 days/month to 1.4 ± 3.7 was observed following LTG initiation, with 79.7% mean reduction (p < 0.001). The overall response rate was 85.2%. The average dose of LTG was 149.6 mg ± 70.5. Twenty-nine patients had adverse events (AE), the most common type was skin changes, and 5 dropped out of the treatment due to AEs.
Discussion:
The results indicate that LTG is associated with a reduction in aura frequency and is well-tolerated in patients whose migraine burden is dominated by the aura phase. LTG is a preventive option worthy of further evaluation in controlled trials.
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...